Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ADH5 | P11766 | 2/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL9800710 | 0.84 | CYP3A4 (0.78) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Trifluoroacetic Acid SCHEMBL2072297 | 0.84 | CYP11B1 (0.73) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Trifluoroacetic Acid SCHEMBL4413259 | 0.84 | CYP11B1 (0.73) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL1524370 | 0.84 | CYP3A4 (0.66) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL27843190 | 0.84 | CYP3A4 (0.66) | CYP3A4MEN1KMT2AALOX15TSHR | |
| SCHEMBL451 | 0.84 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Bromide SCHEMBL1954236 | 0.82 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Ammonia Solution, Strong SCHEMBL3848736 | 0.82 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Hydrochloric Acid SCHEMBL8898731 | 0.82 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AALOX15TSHR | |
| Phosphine SCHEMBL28849690 | 0.82 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | disclosed |
| CN-109071579-B | Method for producing monomer for single-stranded nucleic acid molecule | 住友化学株式会社 | 2021-05-14 | — | — | CN | disclosed |
| EP-3450439-B1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | SUMITOMO CHEMICAL CO (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-3634972-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | Teva Czech Industries s.r.o. (CZ) | 2020-04-15 | — | — | EP | disclosed |
| US-10308672-B2 | Method for producing monomer for single-stranded nucleic acid molecule | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190100540-A1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-04 | — | — | US | disclosed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | CYP3A4 2408/4885MEN1 2981/4885KMT2A 80/4885 |
| US-10308672-B2 | Method for producing monomer for single-stranded nucleic acid molecule | DNA2, POLM, POLRMT | CYP3A4 1953/4885MEN1 1053/4885KMT2A 1873/4885 |
| US-20190100540-A1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | DNA2, POLM, POLRMT | CYP3A4 1953/4885MEN1 1053/4885KMT2A 1873/4885 |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | UNG, SAMHD1, ALKBH1 | CYP3A4 171/4885MEN1 3389/4885KMT2A 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.